Monte Rosa Therapeutics, Inc.: stock overview

GLUENASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$9.37

November 13, 2026Market cap $801M

DCF calculator

What Ploutos Investor adds for Monte Rosa Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 3 fiscal years, from 2023
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Monte Rosa Therapeutics had revenue of $70M over the last 12 months and a net loss of $131M. It holds more cash than debt, by $578M. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$801M
85.45M shares
P/E
–
Revenue, 12 months
$70M
Net margin
-186.2%
2025: -31.2%, above 27% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $427M
$801M
Enterprise value 
$223M
P/E 
–
EV / EBIT 
–
EV / Revenue 
3.2
P/B 3-year median: 1.9
1.6
FCF yield 3-year median: -2.2%
–
Earnings yield 
–

Profitability

Operating margin 
-214.5%
Net margin 
-186.2%
ROIC 
-30.0%
ROIC, 5-year average 
-36.8%
ROE 
-33.0%

Growth

Revenue, yearly change 
+63.5%
EPS, yearly change 
–
FCF, yearly change 
-172.4%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$578M
Total debt 
$36M
Of which operating leases 
$36M
Net cash 
$578M
Net debt / EBITDA 
–
Interest cover 
–
Current ratio 
10.32

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+30.1%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Operating margin

-43.8%

Above 25% of the 285 companies in its industry, and 8% of all.

Net margin

-31.2%

Above 27% of the 302 companies in its industry, and 10% of all.

ROE

-16.6%

Above 37% of the 267 companies in its industry, and 15% of all.

ROA

-8.6%

Above 36% of the 313 companies in its industry, and 16% of all.

Revenue growth

63.5%

Above 89% of the 292 companies in its industry, and 96% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
Monte Rosa Therapeutics, Inc.
CIK
1826457
Exchange
NASDAQ
Industry (SIC)
2836 · Biological Products, (No Diagnostic Substances)
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
85.45M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Monte Rosa Therapeutics's filings show?

These are Monte Rosa Therapeutics's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about GLUE

Didn't find what you were looking for?

Ask us
What is GLUE's market cap?

Monte Rosa Therapeutics, Inc.'s market cap is $801M, at a price of $9.37 on November 13, 2026 and 85.45M shares.

How much revenue does GLUE have?

Monte Rosa Therapeutics had revenue of $70M over the last 12 months.

Does GLUE pay a dividend?

No. Monte Rosa Therapeutics paid no regular dividend over the last 12 months.

Where do the figures come from?

From Monte Rosa Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.